Nov 10 2022
BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022.
Nov 09 2022
BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences.
Sep 06 2022
Large multi-site COVID-19 study to use IsoPlexis Single Cell Functional Proteomics to survey immunity. BRANFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IsoPlexis  (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a
Aug 10 2022
BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 2022.
May 11 2022
First quarter 2022 revenue increased 52% over prior year period BRANFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Revenue of $4.9 million for
Displaying 1 - 10 of 18